DEST - Destiny Pharma says XF-73 now very well positioned for a partnering programme
(NewsDirect)
Destiny Pharma PLC (AIM:DEST, OTC:DTTYF)CEO Neil Clark speaks to Thomas Warner from Proactive after releasingthe clinical-stage biotechnology company's full year results for2022.
Clark says that DestinyPharma is focused on finding a partner for its lead asset, XF-73, anasal gel that decolonizes patients before surgery to preventpost-surgical infections.
He adds that the asset is now"very well positioned" for a partneringprogramme.
Contact Details
Proactive UKLtd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.